Highlights
…for some patients, for example that have a high disease burden but otherwise fit and well, I would prefer in the first-line setting to use the quadruplet, especially patients that have liver metastases, but not only limited to liver metastases, a high bulk of disease.
The patients that have PD-L1 expression more than 50%, about 20% of them will get the single-agent pembrolizumab, 80% will get the triplet. The patients that have less than 50% PD-L1 expression, the vast proportion will get the triplet, and a small proportion will get the quadruplet.
This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for non-small cell lung cancer (NSCLC). Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include AMG 510, MRTX849, capmatinib, tepotinib, TAK-788, poziotinib, pralsetinib, and selpercatinib.